ABL DiagnosticsXPAR:ABLD +0.76%51 EBITDA Margin % is 15.78% as of Dec. 2025, which is 8% above its 10-year median of 14.58. GuruFocus rates XPAR:ABLD with a GF Score™ of 51/100 and a GF Value™ of €7.71 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 664 Healthcare Providers & Services companies, ABL Diagnostics ranks better than 60.69% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. ABL Diagnostics's EBITDA for the
six
months ended in Dec. 2025 was €0.65 Mil. ABL Diagnostics's Revenue for the
six
months ended in Dec. 2025 was €4.10 Mil. Therefore, ABL Diagnostics's EBITDA margin for the quarter that ended in Dec. 2025 was 15.78%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
ABL Diagnostics EBITDA Margin % Related Terms
ABL Diagnostics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for ABL Diagnostics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:ABLD vs VEEV, BTSG, TEM: EBITDA Margin % Comparison
For the Health Information Services subindustry, ABL Diagnostics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ABL Diagnostics EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, ABL Diagnostics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where ABL Diagnostics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABL Diagnostics (XPAR:ABLD) has a EBITDA Margin % of 15.78% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on ABL Diagnostics and its competitors. This is near median its historical median of 14.58. Over the past decade, ABL Diagnostics' EBITDA Margin % has ranged from 0.80 to 169.97. According to the industry distribution chart, ABL Diagnostics ranks #261 out of 664 companies in the Healthcare Providers & Services industry, placing it in the top 39.3%.
Is ABL Diagnostics' EBITDA Margin % too high?
ABL Diagnostics' current EBITDA Margin % of 15.78% is near median its 10-year median of 14.58. Over the past 10 years, this metric has ranged from a low of 0.80 to a high of 169.97. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. ABL Diagnostics' value of 15.78% is 54.6% above this industry median. Based on the distribution chart, ABL Diagnostics ranks #261 out of 664 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, ABL Diagnostics has a GF Score™ of 51/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ABL Diagnostics' EBITDA Margin % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, ABL Diagnostics ranks #261 out of 664 companies for EBITDA Margin %. This puts ABL Diagnostics in the upper half of its industry. The industry median EBITDA Margin % is 10.21. ABL Diagnostics' value of 15.78% is 54.6% above this benchmark. Historically, ABL Diagnostics' own EBITDA Margin % has ranged from 0.80 to 169.97 over the past decade. While the company's 10-year median is 14.58 vs. the industry median of 10.21, ABL Diagnostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 664 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ABL Diagnostics's current EBITDA Margin % of 15.78% is 54.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on ABL Diagnostics and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ABL Diagnostics's current EBITDA Margin % is 15.78%, which is near median its own 10-year median of 14.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ABL Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, ABL Diagnostics (XPAR:ABLD) is currently considered Significantly Undervalued. The stock's GF Value™ is €7.71, compared to a current price of €2.66 — trading 65.5% below its estimated fair value. The current EBITDA Margin % is 15.78%, which is near median its 10-year median of 14.58 and 54.6% above the Healthcare Providers & Services industry median of 10.21. ABL Diagnostics' overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For ABL Diagnostics (XPAR:ABLD), the current EBITDA Margin % is 15.78% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ABL Diagnostics (XPAR:ABLD) Overvalued in 2026?
Based on GuruFocus' analysis, ABL Diagnostics stock appears to be undervalued.
The current stock price of €2.66 is trading 65.5% below its estimated GF Value™ of €7.71.
GuruFocus considers ABL Diagnostics to be Significantly Undervalued.
Key valuation signals for XPAR:ABLD:
EBITDA Margin %: 15.78% (near median its 10-year median of 14.58)
GF Value™: €7.71 vs. price of €2.66 (65.5% below fair value)
Industry Position: 54.6% above the Healthcare Providers & Services median (#261 of 664)
No single metric tells the full story. See the XPAR:ABLD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ABL Diagnostics is a diagnostic and medical software company. The group has focused on the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. It also develops, manufactures, and markets kits for clinical specimen collection.
51GF Score
Get the complete analysis for XPAR:ABLD
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ABLD has been successfully added to your 
